| Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial |
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data |
globenewswire.com |
2025-01-13 21:55:00 |
Czytaj oryginał (ang.) |
| Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate |
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. |
globenewswire.com |
2024-12-02 18:01:00 |
Czytaj oryginał (ang.) |
| VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates |
VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. |
zacks.com |
2024-11-13 20:20:22 |
Czytaj oryginał (ang.) |
| Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript |
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-11-13 20:19:35 |
Czytaj oryginał (ang.) |
| Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results |
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate |
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator — |
globenewswire.com |
2024-09-30 20:12:00 |
Czytaj oryginał (ang.) |
| Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart. |
globenewswire.com |
2024-08-30 12:00:00 |
Czytaj oryginał (ang.) |
| Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside |
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines. |
benzinga.com |
2024-08-15 17:57:40 |
Czytaj oryginał (ang.) |
| Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript |
Vaxart, Inc. (NASDAQ:VXRT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - CFO Conference Call Participants Elaine Kim - Cantor Fitzgerald Operator Greetings and welcome to the Vaxart Business Update and Second Quarter 2024 financial results, conference call, a question and answer session will follow management's opening remarks. Individual investors may submit written questions to IR at vaxart.com As a reminder, this conference is being recorded. |
seekingalpha.com |
2024-08-09 00:51:03 |
Czytaj oryginał (ang.) |
| VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates |
VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03. |
zacks.com |
2024-08-08 22:31:04 |
Czytaj oryginał (ang.) |
| Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results |
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats |
globenewswire.com |
2024-08-08 20:01:00 |
Czytaj oryginał (ang.) |
| Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 |
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. |
globenewswire.com |
2024-08-02 12:00:00 |
Czytaj oryginał (ang.) |
| Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding |
Vaxart Inc is developing oral vaccines for COVID-19, norovirus, and influenza with promising early clinical results but financial struggles. Vaxart received $453M funding from BARDA for a 10,000-patient Phase 2b trial comparing their COVID-19 oral vaccine to an mRNA vaccine. Despite a stock price spike following the news, Vaxart faced investor disappointment with a $40M offering shortly after the BARDA funding announcement. |
seekingalpha.com |
2024-06-27 12:00:00 |
Czytaj oryginał (ang.) |
| Vaxart Provides Business Update |
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform. |
globenewswire.com |
2024-06-17 20:05:00 |
Czytaj oryginał (ang.) |
| Vaxart Announces $40 Million Underwritten Offering of Common Stock |
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 17, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-06-13 23:07:00 |
Czytaj oryginał (ang.) |
| Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate |
— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — |
globenewswire.com |
2024-06-13 20:15:00 |
Czytaj oryginał (ang.) |
| Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common stock to one new non-executive employee to induce him to accept employment with Vaxart. |
globenewswire.com |
2024-05-23 20:01:00 |
Czytaj oryginał (ang.) |
| Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript |
Vaxart, Inc. (NASDAQ:VXRT ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean Tucker - Founder and Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - Chief Financial Officer Conference Call Participants Madison Britt Wynne El-Saadi - B. Riley Securities Aseah Khan - Cantor Fitzgerald Liang Cheng - Jefferies Operator Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-05-13 21:49:08 |
Czytaj oryginał (ang.) |
| Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results |
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the effect of the disease in infants |
globenewswire.com |
2024-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers |
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate. |
globenewswire.com |
2024-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024? |
The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump. |
investorplace.com |
2024-04-09 20:30:00 |
Czytaj oryginał (ang.) |